Sensirion is part of a CHF 4 million Series A financing round of MaxWell Biosystems AG, a spin-off of ETH Zurich founded in 2016, to further industrialize and scale-up the production of their consumables, so-called multiwell high-density microelectrode array (HD-MEA) plates.   Such scale-up will enable the customers of MaxWell Biosystems in the pharmaceutical industry to run functional drug screenings at a higher throughput and ultimately contribute to accelerating the development of drugs t...